At #EAU25, Dr. Fred Saad presented new insights from the PEACE-3 trial (NCT02194842), a multicenter study evaluating enzalutamide ± radium-223 in men with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases.
In a subgroup of 115 patients enrolled before the 2018 safety update, the addition of bone-protective agents (BPAs) like zoledronic acid or denosumab showed clear clinical benefit:
Median rPFS extended from 13 to 27 months with BPA (HR=0.61)
Median OS improved from 28 to 41 months (HR=0.61)
ENZ-RAD + BPA led to an impressive median OS of 60 months
These findings suggest that BPAs may not only reduce skeletal events, but also enhance the efficacy of systemic therapies in mCRPC.
The study was led by Dr. Saad with contributions from an outstanding international team, including Dr. Silke Gillessen, Dr. LORIOT Yohann, Dr. Enrique Gallardo, Dr. Antonio Rodriguez-Vida, and Dr. Bertrand Tombal, among others.
For more details: https://lnkd.in/dY7C4Btp
